BMS says Hengrui’s Abraxane infringes
13-05-2022
BMS sues over generic of blockbuster leukaemia treatment
04-10-2021
BMS, Pfizer win patent dispute over blockbuster drug, Eliquis
06-09-2021
nitpicker / Shutterstock.com
Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst (Pomalidomide), which it claims infringes six patents owned by BMS’ subsidiary Celgene.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
BMS, Celgene, MSN Laboratories, Pomalyst, generics, ANDA, Food and Drug Administration
